Program
insulin degludec
Also written as “insulin degludec/insulin aspart”, “insulin degludec/liraglutide” and “Insulin degludec”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 5 companies.
Drug pageInsulin degludec: every studyMany companies study it; this page follows only the 105 they lead. All 128 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1000 open or running | phase 4since Sep 21, 2018 | Jan 30, 2008 | none ahead |
| Tonghua Dongbao Pharmaceuticalits history only | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Gan & Lee Pharmaceuticalsits history only | 11 open or running | phase 1since Aug 18, 2025 | Aug 18, 2025 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 3since Jul 5, 2021 | Jul 5, 2021 | none ahead |
| Sunshine Lake Pharmaits history only | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since May 31, 2011.
- May 3, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02762578, NCT02773368
- Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
- Sep 15, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02906917, NCT02911948
- Mar 10, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03078478 · 1,609 enrolled · United States, Canada, Denmark and more
- May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
- Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
- Nov 16, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03377699 · 225 enrolled · Argentina, Australia, Austria and more
- Sep 21, 2018Phase 4 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT03687827 · 498 enrolled · United States, Canada, Poland and more
- Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
- Jul 5, 2021Sino Biopharmaceutical’s first study: phase 3 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04955834 · 344 planned · China
- Mar 6, 2023Sunshine Lake Pharma’s first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
- Jun 2, 2024Tonghua Dongbao Pharmaceutical’s first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
- Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
- Aug 18, 2025Gan & Lee Pharmaceuticals’ first study: phase 1 study in Diabetes Mellitus, Type 2New to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT07146347 · 14 planned · Germany
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07146347Diabetes Mellitus, Type 2 · Germany | 1 | Recruiting | Gan & Lee Pharmaceuticals | Apr 1, 2026 | 14 |
| NCT06559722Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Tonghua Dongbao Pharmaceutical | Oct 2025 | 510 |
| NCT06449703Healthy · China | 1 | Recruiting | Tonghua Dongbao Pharmaceutical | Jun 16, 2024 | 44 |
| NCT05802862Diabetes Mellitus · China | 3 | Completed | Sunshine Lake Pharma | Aug 16, 2024 | 414 |
| NCT04955834Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Sino Biopharmaceutical | Dec 31, 2025 | 344 |
| NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Novo Nordisk | Jun 23, 2022 | 588 |
| NCT03687827Diabetes Mellitus, Type 2 · United States, Canada, Poland and more | 4 | Completed | Novo Nordisk | Dec 20, 2019 | 498 |
| NCT03377699Diabetes Mellitus · Argentina, Australia, Austria and more | 3 | Completed | Novo Nordisk | Dec 17, 2020 | 225 |
| NCT03292185Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Jan 2, 2018 | 24 |
| NCT03175120Diabetes Mellitus · China, Hong Kong | 3 | Completed | Novo Nordisk | Mar 5, 2019 | 453 |
| NCT03172494Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | Jun 14, 2019 | 720 |
| NCT03078478Diabetes Mellitus · United States, Canada, Denmark and more | 3 | Completed | Novo Nordisk | Feb 13, 2019 | 1,609 |
| NCT02911948Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 17, 2017 | 210 |
| NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more | 3 | Completed | Novo Nordisk | Aug 31, 2017 | 532 |
| NCT02844790Healthy · China | 1 | Completed | Novo Nordisk | Sep 26, 2016 | 24 |
| NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Sep 26, 2017 | 420 |
| NCT02762578Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | May 19, 2017 | 543 |
| NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more | 3 | Completed | Novo Nordisk | Sep 4, 2016 | 263 |
| NCT02607306Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Dec 15, 2017 | 819 |
| NCT02536859Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Apr 14, 2016 | 60 |
| NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Completed | Novo Nordisk | Oct 3, 2018 | 1,012 |
| NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more | 3 | Completed | Novo Nordisk | Oct 5, 2016 | 506 |
| NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Dec 23, 2015 | 420 |
| NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 2015 | 31 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 11, 2016 | 501 |
| NCT02030600Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Dec 4, 2015 | 721 |
| NCT01959529Diabetes Mellitus · United States, Algeria, Argentina and more | 3 | Completed | Novo Nordisk | Oct 16, 2016 | 7,637 |
| NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Nov 4, 2014 | 557 |
| NCT01916174Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2013 | 50 |
| NCT01880736Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Apr 2014 | 458 |
| NCT01868581Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 58 |
| NCT01868568Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2008 | 55 |
| NCT01868555Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Feb 2008 | 32 |
| NCT01868529Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2008 | 63 |
| NCT01865331Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2007 | 32 |
| NCT01865318Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jan 2007 | 36 |
| NCT01865305Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Feb 2007 | 59 |
| NCT01865292Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2006 | 40 |
| NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Completed | Novo Nordisk | May 15, 2014 | 833 |
| NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more | 3 | Completed | Novo Nordisk | Nov 7, 2014 | 362 |
| NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Mar 2014 | 40 |
| NCT01773798Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2013 | 33 |
| NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more | 3 | Completed | Novo Nordisk | Jan 9, 2014 | 274 |
| NCT01704417Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Mar 2013 | 40 |
| NCT01680341Diabetes Mellitus · United States, Algeria, Germany and more | 3 | Completed | Novo Nordisk | Aug 22, 2013 | 272 |
| NCT01676116Diabetes Mellitus · United States, Australia, France and more | 3 | Completed | Novo Nordisk | Mar 11, 2014 | 438 |
| NCT01664247Diabetes Mellitus · United States, Canada, France and more | 3 | Completed | Novo Nordisk | Dec 31, 2013 | 346 |
| NCT01618162Diabetes Mellitus · United States, Bulgaria, Canada and more | 3 | Completed | Novo Nordisk | Oct 23, 2013 | 435 |
| NCT01623375Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Aug 2012 | 18 |
| NCT01590836Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jun 2012 | 22 |
| NCT01570751Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Novo Nordisk | Jan 2014 | 145 |
| NCT01569841Diabetes Mellitus · United States | 3 | Completed | Novo Nordisk | Nov 2012 | 24 |
| NCT01513590Diabetes Mellitus · Algeria, Bulgaria, Croatia and more | 3 | Completed | Novo Nordisk | Nov 19, 2012 | 394 |
| NCT01513473Diabetes Mellitus · United States, Bulgaria, Finland and more | 3 | Completed | Novo Nordisk | Jul 30, 2013 | 350 |
| NCT01467414Diabetes Mellitus · Germany | 1 | Terminated | Novo Nordisk | Dec 2011 | 1 |
| NCT01455142Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Jan 2012 | 32 |
| NCT01437592Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Nov 22, 2011 | 24 |
| NCT01392573Diabetes Mellitus · United States, Bulgaria, Denmark and more | 3 | Completed | Novo Nordisk | Oct 1, 2012 | 413 |
| NCT01388361Diabetes Mellitus · United States, Austria, Belgium and more | 3 | Completed | Novo Nordisk | Jul 2012 | 413 |
| NCT01365507Diabetes Mellitus · United States, Korea, Republic of, Malaysia and more | 3 | Completed | Novo Nordisk | Apr 2012 | 276 |
How it is read
Names in the registry
- “insulin degludec”, 73 entries
- “insulin degludec/insulin aspart”, 35 entries
- “insulin degludec/liraglutide”, 17 entries
- “Insulin degludec”, 4 entries
- “Insulin degludec/liraglutide”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 58 studies
- Diabetes Mellitus, Type 1, 31 studies
- Diabetes Mellitus, 16 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.